Candriam S.C.A. Reduces Holdings in Mirum Pharmaceuticals, Inc. $MIRM

Candriam S.C.A. decreased its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 2.6% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 373,005 shares of the company’s stock after selling 9,974 shares during the period. Candriam S.C.A. owned approximately 0.75% of Mirum Pharmaceuticals worth $18,983,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in MIRM. CWM LLC grew its holdings in Mirum Pharmaceuticals by 259.4% during the 1st quarter. CWM LLC now owns 593 shares of the company’s stock valued at $27,000 after purchasing an additional 428 shares during the last quarter. Comerica Bank boosted its position in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the period. Quarry LP purchased a new position in shares of Mirum Pharmaceuticals during the first quarter valued at approximately $56,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Mirum Pharmaceuticals by 14.9% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,914 shares of the company’s stock valued at $97,000 after buying an additional 248 shares during the last quarter. Finally, Avanza Fonder AB raised its holdings in shares of Mirum Pharmaceuticals by 44.3% in the second quarter. Avanza Fonder AB now owns 4,154 shares of the company’s stock worth $211,000 after buying an additional 1,276 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Raymond James Financial restated a “strong-buy” rating on shares of Mirum Pharmaceuticals in a report on Thursday, August 7th. Morgan Stanley boosted their target price on shares of Mirum Pharmaceuticals from $75.00 to $81.00 and gave the company an “overweight” rating in a research note on Thursday, October 16th. Cantor Fitzgerald upped their price target on shares of Mirum Pharmaceuticals from $85.00 to $95.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Wednesday, November 5th. Finally, Evercore ISI boosted their price objective on shares of Mirum Pharmaceuticals from $77.00 to $89.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $84.91.

Mirum Pharmaceuticals Stock Performance

MIRM stock opened at $69.25 on Friday. Mirum Pharmaceuticals, Inc. has a 1-year low of $36.88 and a 1-year high of $78.54. The business has a 50-day moving average price of $72.63 and a 200 day moving average price of $59.78. The company has a market capitalization of $3.56 billion, a P/E ratio of -80.52 and a beta of 0.75. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The business had revenue of $133.01 million for the quarter, compared to the consensus estimate of $130.11 million. During the same quarter last year, the firm posted ($0.30) EPS. The company’s revenue for the quarter was up 47.1% on a year-over-year basis. Mirum Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Eric Bjerkholt sold 9,578 shares of the business’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $76.01, for a total value of $728,023.78. Following the completion of the transaction, the chief financial officer directly owned 39,945 shares of the company’s stock, valued at approximately $3,036,219.45. The trade was a 19.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Laura Brege sold 17,000 shares of the company’s stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $74.40, for a total value of $1,264,800.00. Following the sale, the director owned 15,703 shares of the company’s stock, valued at $1,168,303.20. This trade represents a 51.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 14.36% of the company’s stock.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.